Tanabe Pharma America
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tanabe Pharma America sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).
Tanabe Pharma America: 18 sponsored US clinical trials, 2 recruiting.
Tanabe Pharma America sponsors 18 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 13 completed. 7 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Menopause Hot Flashes, with 1 trials.
Top-decile sponsor footprint
Tanabe Pharma America ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
18 total, page 1 of 1
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
NCT05005975
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
NCT06144840
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
NCT05241535
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
NCT05151471
Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
NCT04683848
Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
NCT04793295
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
NCT04440592
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
NCT04569084
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT04577404
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria
NCT04402489
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury
NCT04096950
Safety Study of Oral Edaravone Administered in Subjects With ALS
NCT04165824
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476
Safety and Efficacy Study of MT-2990 in Women With Endometriosis
NCT03840993
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria
NCT03520036
Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
NCT03541200
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
NCT03291067
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 6 |
| Phase 3 | 7 |
What is open in the Tanabe Pharma America pipeline
2 recruiting of 18 indexed (11% open); 13 completed (72%).
Phase mix: 7 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: Menopause Hot Flashes (1 trial), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tanabe Pharma America: open-pipeline peers nationwide
Peers matched on 18 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Tanabe Pharma America sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 18 trials (± recruiting share)
- ADC Therapeutics S.A. · 18 trials · 11% recruiting
- Akros Pharma · 18 trials · 0% recruiting
- AO Clinical Investigation and Publishing Documentation · 18 trials · 0% recruiting
- AO Innovation Translation Center · 18 trials · 33% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
- Aprea Therapeutics · 11% recruiting · 9 trials
Related
What to do with this Tanabe Pharma America page
18 registered trials is a research-attention snapshot, not an endorsement of Tanabe Pharma America or any single study.
- 2 of Tanabe Pharma America's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Menopause Hot Flashes is the condition Tanabe Pharma America studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Menopause Hot Flashes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Tanabe Pharma America pipeline card: 18 registered trials from official public datasets.Report a data error.